cp wire

CP Wire Articles

Under Fire for Risk/Efficacy Profile – Nuplazid Shows Potential for Treating Dementia-Related Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced on 9/10/18 publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and... read more

Mon, 09/10/18 - 09:53 am
Scilex Raises $140 Million to Support Commercialization of Non-Opioid Topical Pain Medication System
  • One analyst predicts peak revenue of 1.1billion in 2025
  • Over 1.1 million lidocaine patches sold in the US in 2017


Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“... read more

Mon, 09/10/18 - 09:13 am
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
  • CABOMETYX is the only preferred tyrosine kinase inhibitor (TKI) treatment option for first-line patients in the poor- and intermediate-risk groups (Category 2A)
  • CABOMETYX is a... read more
Fri, 09/7/18 - 09:44 am
Synthetic Biologics Announces Trial with Cedars-Sinai to Study SYN-010 for the Treatment of IBS-C

Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today... read more

Thu, 09/6/18 - 12:16 pm
Synlogic Reports Positive Interim Ph I/IIa Data for Microbiome Based Treatment for Phenylketonuria

Synlogic, Inc., (Nasdaq:SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced positive interim clinical data from the healthy... read more

Thu, 09/6/18 - 12:03 pm

Pages